Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PRX-112 · 2 trials · 1 indication
| Name | Type | Description |
|---|---|---|
| PRX-112 | DRUG | - |
PRX-112 is an investigational small molecule being developed for the treatment of Gaucher disease, a rare genetic disorder. It is currently in Phase 2 clinical development and has not been approved by regulatory authorities.
PRX-112 is being developed by Protalix BioTherapeutics, Inc., a biopharmaceutical company traded on the stock exchange under the ticker symbol PLX.
PRX-112 is in Phase 2 clinical development. It has completed two clinical trials, including a Phase 1 study and a Phase 2 open-label dose escalation study, both in patients with Gaucher disease.
PRX-112 has completed two clinical trials: NCT01747980, a Phase 1 study evaluating safety and pharmacokinetics in 16 Gaucher disease patients, and NCT02107846, a Phase 2 open-label dose escalation study in 10 patients. Both trials are completed.
PRX-112 is a small molecule designed to treat Gaucher disease. The specific molecular target or mechanism of action has not been disclosed in available information.